DIPRIVAN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Diprivan, and what generic alternatives are available?
Diprivan is a drug marketed by Fresenius Kabi Usa and is included in one NDA. There is one patent protecting this drug.
This drug has one patent family member in one country.
The generic ingredient in DIPRIVAN is propofol. There are twelve drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the propofol profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Diprivan
A generic version of DIPRIVAN was approved as propofol by SAGENT PHARMS INC on January 4th, 1999.
Summary for DIPRIVAN
| International Patents: | 1 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 135 |
| Clinical Trials: | 139 |
| Patent Applications: | 3,944 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for DIPRIVAN |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for DIPRIVAN |
| What excipients (inactive ingredients) are in DIPRIVAN? | DIPRIVAN excipients list |
| DailyMed Link: | DIPRIVAN at DailyMed |
Recent Clinical Trials for DIPRIVAN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Jenna L Leclerc MD, PhD | Phase 2/Phase 3 |
| Hong Kong Children's Hospital | Phase 4 |
| The University of Hong Kong | Phase 4 |
Pharmacology for DIPRIVAN
| Drug Class | General Anesthetic |
| Physiological Effect | General Anesthesia |
Anatomical Therapeutic Chemical (ATC) Classes for DIPRIVAN
US Patents and Regulatory Information for DIPRIVAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fresenius Kabi Usa | DIPRIVAN | propofol | INJECTABLE;INJECTION | 019627-001 | Oct 2, 1989 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Fresenius Kabi Usa | DIPRIVAN | propofol | INJECTABLE;INJECTION | 019627-002 | Jun 11, 1996 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DIPRIVAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Fresenius Kabi Usa | DIPRIVAN | propofol | INJECTABLE;INJECTION | 019627-002 | Jun 11, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
| Fresenius Kabi Usa | DIPRIVAN | propofol | INJECTABLE;INJECTION | 019627-002 | Jun 11, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
| Fresenius Kabi Usa | DIPRIVAN | propofol | INJECTABLE;INJECTION | 019627-002 | Jun 11, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for DIPRIVAN
See the table below for patents covering DIPRIVAN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Switzerland | 694396 | Pharmazeutische Zusammensetzung mit therapeutischem oder pharmazeutischem Mittel und Edetat. (Sterile oil-in-water emulsions for parenteral administration, containing active agent, e.g. antifungal, anesthetic or anitcancer agent, and edetate to inhibit microbial growth after contamination) | ⤷ Try a Trial |
| United Kingdom | 9405593 | ⤷ Try a Trial | |
| Poland | 322278 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
